Objective: To compare transfusion requirements and erythropoietic response in preterms between schedules of rEPO administration once or three times per week, using the same weekly dose.
Introduction
Several studies have recently focused on the usefulness of recombinant human erythropoietin (rEPO) in preterms having non-hematological problems. 1, 2 However, the fundamental clinical objective of using rEPO in very low birth weight (VLBW) infants has been to slow down the decline in hemoglobin parameters during the first weeks of life and to reduce the transfusion requirement, which is very high for these infants. [3] [4] [5] [6] [7] Since the first pilot trial, published by Halperin et al. in 1990, 8 rEPO use has spread and many studies have evaluated it as safe and effective. [9] [10] [11] [12] In terms of efficacy, rEPO stimulates erythropoiesis in VLBW infants and diminishes the number of transfusions per infant as well as the cumulative volume transfused and the exposure to multiple donors. [10] [11] [12] Nevertheless, habitual use has not been recommended because of the multifactorial causes of the anemia. Control of phlebotomies and the use of strict transfusion criteria by themselves lower the transfusion requirement. 6, 7 Regarding safety, long-term adverse effects are still unknown, 6 but in the short term, rEPO does not increase neonatal morbidity (sepsis, necrotizing enterocolitis, intraventricular hemorrhage, chronic lung disease, death before discharge, hypertension). [10] [11] [12] Nevertheless, because of its demonstrated angiogenic activity, 13 several trials have associated the use of rEPO with retinopathy of prematurity (ROP). 14, 15 Current meta-analyses have shown greater ROP incidence in VLBW infants who received rEPO before day 8 of life. [10] [11] [12] The most suitable dosage schedule, based on pharmacokinetic studies, remains unclear because of differences among studies. Controversy persists concerning dosages of rEPO and iron supplement, the route of administration, the best timing and duration for treatment. [3] [4] [5] 8, [16] [17] [18] [19] [20] [21] [22] In general, VLBW infants are administered higher and more frequent rEPO doses than are children and adults. However, several studies using rEPO twice weekly, have reported positive results in relation to transfusion requirements. 23, 24 These schedules are easier to administer and less painful after hospital discharge. A once-weekly schedule has not been previously proposed.
Our objective is to compare transfusion requirements and erythropoietic response in preterms between schedules of rEPO administration once weekly or three times weekly, using the same weekly dose. 
Methods

Patients
Infants weighing <1500 g at birth and/or were p32 weeks' gestation were consecutively included in this study, on receiving written informed consent from the parents. Infants having lifethreatening congenital malformations, chromosomal anomalies, or significant hemolytic disease were excluded from this study, as were infants with protocol violations (schedules that were altered by mistake). The Hospital Ethics Committee approved the trial.
The patients were randomised into two groups using a computerized random-number generator: Group 1: received subcutaneous rEPO at 250 units kg À1 per dose, three times a week for 6 weeks. Group 2: received subcutaneous rEPO at 750 units kg À1 per dose, once a week for 6 weeks. The rEPO (Epopen) treatment was initiated between days 3 and 15 of life. All patients in both groups received oral ferrous sulfate from day 14 of life. The starting dose was 4 mg kg À1 per day and was increased to 6 mg kg À1 per day, if serum ferritin levels fell below 60 ng ml À1 . Clinicians were not masked to the study group assignment, though the attending neonatologist did not belong to the research group.
The sample size was calculated to study the difference in transfusion requirements and hemoglobin levels at the end of the study. These differences were based on a previous study conducted in our hospital (unpublished data), wherein 75 five preterms of gestational age <34 weeks were included: 40 received subcutaneous rEPO (Group 1), whereas 35 (retrospective control group) received no rEPO. The transfusion requirement was 21 and 57%, and hemoglobin level at the end of study was 9.9 ± 1.4 and 8.1±0.9 g dl À1 , respectively. On the basis of these previous data, we considered at least a 20% difference in transfusion requirements and 1.5 g dl À1 in hemoglobin level to be clinically significant. The sample size was estimated using a two-tailed type-I error of 0.05 and a power of 80%. Finally, 44 VLBW infants were required in each group.
Transfusion criteria
A strict protocol was used to administer transfusions (Table 1) , adapted from previous studies. 4, 5 Infants did not receive a transfusion only to replace phlebotomy. Infants who met transfusion criteria received 15 ml kg À1 of packed red blood cells. Pediatric bags were used, and each infant received only two transfusions from one single donor bag. Generally, when red blood cell was transfused, the red cell storage media was <7 days, or <15 days if radiated blood bags were used.
Measurement of efficacy
Efficacy was measured according to the transfusion requirement (to receive one or more transfusions, number of transfusions per neonate and cumulative volume transfused Kg À1 before day 15 of life and at the end of the study). We also assessed changes in hemoglobin and the erythropoietic response (increase of reticulocyte counts and serum transferrin receptor (sTfR), and decrease of serum ferritin) at end of the study. To avoid interferences of red blood cell transfusion on hematological parameters and to evaluate the real effect of rEPO, we excluded transfused preterms from this specific analysis.
We studied the frequency of adverse effects: chronic lung disease (oxygen necessity at 36 weeks of post-conception age), patent ductus arteriosus, necrotizing enterocolitis, intraventricular Hematocrit p30% or hemoglobin <10 g dl
À1
Infants requiring minimal respiratory support (FiO 2 p0,4 and mechanical ventilation or endotracheal/nasal CPAP <6 cm H 2 O). Significant apnea and bradycardia (>9 episodes in 12-h period or >2 episodes in 24-h requiring bag-mask ventilation). Heart rate >180 beats per min or respiratory rate >80 breaths per min for 24 h. Weight gain <10 g kg À1 per day over the previous 4 days while receiving >100 kcal kg À1 per day.
Undergoing surgery.
Hematocrit p20% or hemoglobin <7 g dl
Asymptomatic with absolute reticulocyte count <100 Â 10 9 l À1 .
Abbreviations: CPAP, continuous positive airway pressure; MAP, mean airway pressure. a Adapted from Meyer MP et al. 4 and Shannon KM et al. 5 hemorrhage, ROP, sepsis, death before discharge and neutropenia (<1.0 Â 10 9 l À1 ) and thrombocytosis (>450 Â 10 9 l À1 ) during treatment. For ROP diagnosis, we carried out eye examinations using indirect ophthalmoscope, starting between week 4 and 6 after delivery. Follow-up examinations were carried out until resolution of ROP or retinal maturation. The international classification of ROP was used to classify severity. 25 Two different pediatric ophthalmologists made these examinations without knowing the group to which each neonate belonged. We did not study the level of agreement between the two ophthalmologists, but all the clinical decisions and treatment options were taken by consensus between them.
Variables studied In addition to measuring efficacy, we compiled data on gestational age (assessed by the date of the last menstruation, ultrasound and physical examination), gender, birth weight, Apgar score at 5 min of life, O 2 requirements in the first 24 h of life, age and weight at beginning of treatment, volume of blood withdrawn (<15th day of life and total), number of transfusions before entering study and exposure to donors. Phlebotomy losses were recorded by nurses.
Nutritional support
All preterms were fed using a standard protocol: starting from X30 kcal kg À1 per day in the first 48 h and increasing to 120 kcal kg À1 per day on day 8. Parenteral nutrition was administered in the first 24 h, whereas enteral nutrition began in the first 72 h, when the clinical situation allowed. We set the folic acid intake at 50 mg per day and 10 units per day of vitamin E from day 14 of life.
Laboratory test
For the hemoglobin and reticulocyte, neutrophil and platelet counts, we used an ADVIA 120 (Dublin, Ireland) counter, serum ferritin was determined by the immunoturbidimetric method in a Hitachi 920 counter (Mito, Japan), and sTfR by enzyme linked immunosorbent assay with the kit 'Quantikine IVD-human sTfR, R&D Systems (Minneapolis, MN, USA). These parameters were determined at beginning of the study, at day 15 of life, and at the end of the study (2.5 cc of blood were required). In addition, we registered the cumulative volume of blood withdrawn for study purposes, from birth to trial completion.
Statistics
For statistical analysis, we used the SPSS version 15.0. and Epidat version 3.0 for sample-size calculations and randomization. Continuous data were expressed as mean ± standard deviation, or standard error and categorical data as percentages. To show the homogeneity of both groups, we used the Student's t-test to compare continuous variables and the w 2 -test for non-continuous variables. Repeated-measures analysis of variance was used to compare the erythropoietic response between treatment groups. The independent inter-group variable was the rEPO administration schedule, whereas the dependent intra-group variables were hemoglobin, reticulocyte counts, serum ferritin and sTfR. Identification of differences between groups was based on Tukey's post hoc test. Statistical significance was set at P<0.5.
Intention to treat was used to analyse the transfusion requirement (to receive one or more transfusions). The relative risk was calculated using a 95% confidence interval (CI). To compare the number of transfusions per infant and cumulative volume of blood transfused per kg we used the Student's t-test, and the Mann-Whitney U-test to compare the exposure to donors.
To compare the incidence of complications, we calculated the relative risk and 95% CI.
Results
A total of 140 VLBW infants were randomized, 70 per group. However, 10 infants were excluded from Group 1 (7 deaths before beginning of treatment, and 3 protocol violations), and 11 were excluded from Group 2 (6 deaths and 5 protocol violations). Finally, 60 infants were evaluated in Group 1 and 59 in Group 2. Table 2 shows the characteristics of the VLBW infants at entry.
Blood transfusions
In each group 13 infants were transfused. The two groups did not differ in relation to the number of transfusions per infant, cumulative volume of blood transfused (cc per kg), or exposure to donors ( Table 3 ). The volume of blood withdrawn was also similar. Eight neonates in Group 1 and 7 in Group 2 needed two or more Figure 1 Changes in hematological parameters during the study in not transfused preterms (a) Hemoglobin: mean values±standard error (95% CI). Anova: P<0.000. Intra-group differences: y P<0.000. Inter-group differences: *P<0.003. (b) Reticulocyte counts: mean values±standard error (95% CI). Anova: P<0.02. Intra-group differences:
z P<0.01; Inter-group differences: not significant. (c) Serum ferritin: mean values±standard error (95% CI). Anova: P<0,000. Intra-group differences: y P<0.000; z P<0.01; w P<0.005. Inter-group differences: not significant. (d) Serum transferrin receptor (sTfR). Anova: P: 0.33; Intra-group and inter-group differences: not significant.
rEPO in VLBW infants
Erythropoietic activity and iron metabolism Figure 1 shows changes in parameters analysed during study in preterms, who received no transfusion. A significant decrease in hemoglobin was detected in both groups (P<0.000). At end of study, hemoglobin levels were lower in the group that followed the weekly schedule (P<0.03). Reticulocyte counts augmented significantly after treatment in both groups (P<0.02), with no differences between them. Serum ferritin significantly fell in both groups (P<0.000). At end of study, 52% preterms in Group 1 and 54.8% in Group 2 had low iron storage (serum ferritin <60 ng ml À1 ), despite adequate iron intake. In both groups, sTfR registered higher values at the end of treatment, but with no significant differences compared with beginning values. In Group 1, the neonates who were transfused showed significantly lower values of hemoglobin than those who needed no transfusions (10.2 ± 1.6 versus 11.5 ± 1.4 g dl À1 , P<0.009). Group 2 had similar values (10.4 ± 1.6 g dl À1 versus 10.6 ± 1.5, P ¼ 0.64).
Complications
No apparent difference was observed between the two groups ( Table 4 ). The high incidence of thrombocytosis during treatment in both groups was notable, although it had no clinical manifestations. The incidence of neutropenia was low and transient.
Seven neonates died, two after finishing treatment because of infectious diseases and the other five, before week 6 of life (three because of respiratory problems and two because of infectious diseases). The distribution of these complications was similar in the two groups.
The overall incidence of ROP was 6.7%. No apparent difference was observed between the two groups. Severe forms of ROP were diagnosed in three patients (two in Group 1 and one in Group 2). In relation to the timing of the rEPO administration (early versus late), there were no differences (three out of the eight cases received rEPO before day 8 of life).
Discussion
Since 1996, we used the standard rEPO dosing schedule discussed for Group 1. Our points of reference were the trial of Marier et al. 3 and a previous study conducted in our hospital that achieved a decrease in transfusion requirements. We studied this new onceweekly schedule because we thought it is less painful for newborns and easier to administer after hospital discharge. In Europe, many health programs use 'early discharge' and domiciliary care. The once-weekly schedule could facilitate continuity of treatment, decrease hospital costs, and help improve the quality of assistance. We have found no studies using the once-weekly administration that we propose.
Most of the studies published have used higher and more frequent rEPO doses in preterms (three to seven doses per week) than in adults, because of the increased clearance and distribution volume observed in preterms. 26 However, the use of a twice-weekly rEPO schedule, has previously shown an adequate erythropoietic response and has proved to be useful for reducing transfusion requirements. 23, 24, 27, 28 As Brown et al., 23 we selected two groups of VLBW infants in order to compare the two different schedules, but a placebo group would have improved our trial quality.
In our study, the number of transfusions per neonate, the cumulative volume of blood transfused per kg and the exposure to donors were low and similar in both groups (Table 3) . These values agree with findings in other studies. [10] [11] [12] We wish to highlight the low volume of blood withdrawn per kg, in comparison with other trials. 3, 17, 21, 23, 29, 30 This fact together with the strict transfusion criteria, could have contributed to the low transfusion requirement observed.
To determine the real impact of rEPO treatment on hematological parameters, we assessed only non-transfused preterms, in order to avoid the effect on erythropoietic activity that a transfusion can cause. This is a new contribution not found in other studies. Similar to other researchers, [30] [31] [32] we have noted a gradual reduction of hemoglobin in both groups, although at the end of study the once-weekly group presented a lower level. If the groups were comparable at entry and the volume withdrawn was similar, the fact that Group 2 had less hemoglobin could be ascribed to the treatment schedule, but these findings have not shown the impact on transfusion requirements.
The greater erythropoietic activity was shown in both groups by an increase but no subsequent change after week 6 in reticulocyte count after rEPO administration (Figure 1 ). These results were expected, having been previously reported. 5, 17, 20, 23, 26, 29, 32 We found no differences between the two treatment groups. Brown et al. 33 Similar to the classical laboratory test concerning iron status, sTfR levels are also difficult to interpret. These values are high in newborns, 34 but very few studies have incorporated this measurement to assess the impact of treatment with rEPO in preterm. The sTfR elevation described in preterms after rEPO administration, could be because of the incentive erythropoiesis and a poor iron status in situations of inadequate supply. 31, 32 In our study, as expected, sTfR increased in both groups at week 3 and 6 of treatment, but the difference was not statistically significant during the study or between groups. However, Figure 1 shows reticulocyte increase and ferritin decrease. Both situations may reflect high erythropoiesis. Ferritin decrease is an indirect marker of erythropoietic stimulation determined by rEPO treatment. Stored iron is consumed to maintain adequate hemoglobin levels. In the middle of the study, iron stores were full and the sTfR elevation observed was probably determined by increased erythropoiesis. The criteria for iron deficiency are less well defined in preterms. We considered a ferritin value <60 ng ml -1 to define poor iron status. At the end of the study, 52% of the preterms in Group 1 and 54.8% in Group 2, had low iron storage. This situation could help to maintain the high sTfR values, but it was difficult to quantify how both factors contributed to the sTfR increase.
23
Previous studies have shown that the treatment with rEPO does not increase morbidity in preterms.
3-5,10-12 Transient neutropenia and thrombocytosis, not associated with clinical manifestation, 8, 17, 35 were described. In our study, the incidence of neutropenia and thrombocytosis were higher in the one-week-dose schedule (Table 4) , but these differences were not statistically significant. In both cases, the effect was transient and had no clinical impact. The incidence of the other adverse effects and death was low and similar in both groups.
The relation between rEPO and ROP deserves special consideration. ROP is a proliferative vascular illness that causes the interruption of normal retinal angiogenesis, and the appearance of a neovascular response. The association between rEPO and ROP is based on the angiogenic action of rEPO. 13, 14 Romagnoli et al.
15
reported an increased risk of ROP when administered in week 1 of life. A recent meta-analysis by Ohlson and Aher 10 showed a greater risk for severe ROP in this subgroup, with a relative risk:1.7 (95% CI: 1.1-2.54) and a number needed to harm: 20 (95% CI: 11-100). The incidence of ROP in Spain at any stage in VLBW preterms <1500 g at birth is 21.3%. 36 Our incidence of ROP was lower in both groups and it was higher in those who received rEPO after the week 1 of life, although without significant differences.
We wish to highlight that the sample size was not calculated to evaluate the adverse effects. Our study is likely underpowered to examine low-frequency end points, and thus our conclusions should be used with caution. No apparent differences in adverse events was observed between two groups, but it is possible that this would be significant if more infants were studied.
In conclusion, the one-weekly schedule of rEPO for VLBW infants is as effective as the standard schedule, in relation to transfusion requirement and erythropoietic activity. The weekly administration of rEPO is less painful for the infant and easier to administer after hospital discharge. Therefore, it facilitates treatment compliance. Although we have not found any relation between ROP and early rEPO administration, current systematic reviews advise not to use it before day 8 of life.
